```
=> file reg
FILE 'REGISTRY' ENTERED AT 16:21:42 ON 10 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:    9 SEP 2002  HIGHEST RN 448894-79-9
DICTIONARY FILE UPDATES:   9 SEP 2002  HIGHEST RN 448894-79-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d rn cn 16

L6   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN   56-81-5  REGISTRY
CN   1,2,3-Propanetriol (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Glycerol (8CI)
CN   Propanetriol (7CI)
OTHER NAMES:
CN   1,2,3-Trihydroxypropane
CN   Glycerin
CN   Glycerine
CN   Glyceritol
CN   Glycyl alcohol
CN   Glyrol
CN   Glysanin
CN   Osmoglyn
CN   Pricerine 9091
CN   Trihydroxypropane


=> d rn cn 17

L7   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN   87-99-0  REGISTRY
CN   Xylitol (6CI, 8CI, 9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Klinit
CN   Kylit
CN   Wood sugar alcohol
CN   Xylisorb
CN   Xylite
CN   Xylite (sugar)
CN   Xylitol C
CN   Xylitol CM 90
CN   Xyliton


=> d rn cn 18
```

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 50-70-4 REGISTRY
CN D-Glucitol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glucitol, D- (8CI)
CN **Sorbitol (7CI)**
OTHER NAMES:
CN (-)-Sorbitol
CN C*Sorbidex
CN Cholaxine
CN D-(-)-Sorbitol
CN D-Sorbitol
CN D-Sorbol
CN Diakarmon
CN Esasorb
CN Foodol D 70
CN Glucarine
CN Glucarine (sorbitol syrup)
CN Glucitol
CN Karion
CN Karion (carbohydrate)
CN Karion instant
CN Kyowa Powder 50M
CN L-Gulitol
CN Multitol
CN Neosorb
CN Neosorb 20/60DC
CN Neosorb 70/02
CN Neosorb 70/70
CN Neosorb P 20/60
CN Neosorb P 60
CN Nivitin
CN Sionit
CN Sionit K
CN Sionite
CN Sionon
CN Siosan
CN Sorbex M
CN Sorbex R
CN Sorbex Rp
CN Sorbex S
CN Sorbex X
CN Sorbilande
CN Sorbit
CN Sorbit D 70
CN Sorbit Kyowa Powder 50M
CN Sorbit L 70
CN Sorbit S
CN Sorbit T 70
CN Sorbit W 70
CN Sorbit W-Powder
CN Sorbit WP
CN Sorbite
CN Sorbitol F
CN Sorbitol FP
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

=> d rn cn l9 1-2

L9 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2002 ACS
RN 87-78-5 REGISTRY
CN **Mannitol (8CI, 9CI)** (CA INDEX NAME)
OTHER NAMES:
CN Mannidex 16700

L9 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2002 ACS
RN 69-65-8 REGISTRY
CN D-Mannitol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cordycepic acid (6CI, 7CI)
CN Mannitol, D- (8CI)
OTHER NAMES:
CN D-(-)-Mannitol
CN Diosmol
CN Isotol
CN Maniton S
CN Manna sugar
CN Mannidex
CN Mannigen
CN Mannistol
CN Mannit
CN Mannite
CN **Mannitol**
CN Mannitolum
CN Mannogem 2080
CN Marine Crystal
CN Osmitrol
CN Osmosal

=> d rn cn l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 148553-50-8 REGISTRY
CN Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S)-
OTHER NAMES:
CN CI 1008
CN PD 144723
CN **Pregabalin**

=> d rn cn l11

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 60142-96-3 REGISTRY
CN Cyclohexaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-(Aminomethyl)cyclohexaneacetic acid
CN CI 945
CN **Gabapentin**
CN Go 3450
CN GOE 2450
CN Neurontin

=> file caplus; d que l23; d que l25
FILE 'CAPLUS' ENTERED AT 17:19:09 ON 10 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

FILE COVERS 1907 - 10 Sep 2002 VOL 137 ISS 11
FILE LAST UPDATED: 9 Sep 2002 (20020909/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L6	1	SEA FILE=REGISTRY ABB=ON PLU=ON	GLYCEROL/CN
L7	1	SEA FILE=REGISTRY ABB=ON PLU=ON	XYLITOL/CN
L8	1	SEA FILE=REGISTRY ABB=ON PLU=ON	SORBITOL/CN
L9	2	SEA FILE=REGISTRY ABB=ON PLU=ON	MANNITOL/CN
L10	1	SEA FILE=REGISTRY ABB=ON PLU=ON	PREGABALIN/CN
L11	1	SEA FILE=REGISTRY ABB=ON PLU=ON	GABAPENTIN/CN
L12	143502	SEA FILE=CAPLUS ABB=ON PLU=ON	L6 OR GLYCEROL OR GLYCERIN? OR GLYCYL ALCOHOL
L13	26743	SEA FILE=CAPLUS ABB=ON PLU=ON	L9 OR MANNITOL?
L14	5934	SEA FILE=CAPLUS ABB=ON PLU=ON	L7 OR XYLITO?
L15	41190	SEA FILE=CAPLUS ABB=ON PLU=ON	L8 OR SORBIT? OR NEOSORB?
L16	99	SEA FILE=CAPLUS ABB=ON PLU=ON	L10 OR PREGABALIN OR CI 1008 OR PD 114723
L17	779	SEA FILE=CAPLUS ABB=ON PLU=ON	L11 OR GABAPENTIN OR GO 3450 OR GOE 2450 OR NEURONTIN
L18	25	SEA FILE=CAPLUS ABB=ON PLU=ON	(L16 OR L17) AND (L12 OR L13 OR L14 OR L15)
L22	2	SEA FILE=CAPLUS ABB=ON PLU=ON	SWEETENING AGENTS/CT AND L18
L23	1	SEA FILE=CAPLUS ABB=ON PLU=ON	L22 NOT SOLID/TI

L6	1	SEA FILE=REGISTRY ABB=ON PLU=ON	GLYCEROL/CN
L7	1	SEA FILE=REGISTRY ABB=ON PLU=ON	XYLITOL/CN
L8	1	SEA FILE=REGISTRY ABB=ON PLU=ON	SORBITOL/CN
L9	2	SEA FILE=REGISTRY ABB=ON PLU=ON	MANNITOL/CN
L10	1	SEA FILE=REGISTRY ABB=ON PLU=ON	PREGABALIN/CN
L11	1	SEA FILE=REGISTRY ABB=ON PLU=ON	GABAPENTIN/CN
L12	143502	SEA FILE=CAPLUS ABB=ON PLU=ON	L6 OR GLYCEROL OR GLYCERIN? OR GLYCYL ALCOHOL
L13	26743	SEA FILE=CAPLUS ABB=ON PLU=ON	L9 OR MANNITOL?
L14	5934	SEA FILE=CAPLUS ABB=ON PLU=ON	L7 OR XYLITO?
L15	41190	SEA FILE=CAPLUS ABB=ON PLU=ON	L8 OR SORBIT? OR NEOSORB?
L16	99	SEA FILE=CAPLUS ABB=ON PLU=ON	L10 OR PREGABALIN OR CI 1008 OR PD 114723

```
L17          779 SEA FILE=CAPLUS ABB=ON  PLU=ON  L11 OR GABAPENTIN OR GO 3450
                 OR GOE 2450 OR NEURONTIN
L18           25 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L16 OR L17) AND (L12 OR L13
                 OR L14 OR L15)
L21           11 SEA FILE=CAPLUS ABB=ON  PLU=ON  L18 AND (?LIQUID? OR ?AQUEOUS?
                 OR SOLUTION?)
L24            6 SEA FILE=CAPLUS ABB=ON  PLU=ON  L21 NOT (MEMBRANE OR SOLID OR
                 NITROUS)/TI
L25            5 SEA FILE=CAPLUS ABB=ON  PLU=ON  L21 NOT L24


=> s l23 or l25
L57            6 L23 OR L25

=> file embase; d que l41
FILE 'EMBASE' ENTERED AT 17:19:26 ON 10 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V.  All rights reserved.

 FILE COVERS 1974 TO 5 Sep 2002 (20020905/ED)

 EMBASE has been reloaded. Enter HELP RLOAD for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


L33           40 SEA FILE=EMBASE ABB=ON  PLU=ON  PREGABALIN/CT
L34         3100 SEA FILE=EMBASE ABB=ON  PLU=ON  GABAPENTIN/CT
L35         9616 SEA FILE=EMBASE ABB=ON  PLU=ON  GLYCEROL/CT
L36         1280 SEA FILE=EMBASE ABB=ON  PLU=ON  XYLITOL/CT
L37        11637 SEA FILE=EMBASE ABB=ON  PLU=ON  MANNITOL/CT
L38         3955 SEA FILE=EMBASE ABB=ON  PLU=ON  SORBITOL/CT
L39           20 SEA FILE=EMBASE ABB=ON  PLU=ON  (L33 OR L34) AND (L35 OR L36
                 OR L37 OR L38)
L40            5 SEA FILE=EMBASE ABB=ON  PLU=ON  L39 AND ORAL DRUG ADMINISTRATIO
                 N/CT
L41            1 SEA FILE=EMBASE ABB=ON  PLU=ON  L40 AND ORAL/TI


=> file wpid; d que 156
FILE 'WPIDS' ENTERED AT 17:19:46 ON 10 SEP 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE LAST UPDATED: 06 SEP 2002              <20020906/UP>
MOST RECENT DERWENT UPDATE           200257   <200257/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> The BATCH option for structure searches has been
    enabled in WPINDEX/WPIDS and WPIX  >>>

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY >>>

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
    SEE http://www.derwent.com/dwpi/updates/dwpicov/index.html <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
    PLEASE VISIT:
 http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
    GUIDES, PLEASE VISIT:
```

http://www.derwent.com/userguides/dwpi_guide.html <<<

```
L49          31 SEA FILE=WPIDS ABB=ON  PLU=ON  PREGABALIN OR CI 1008 OR PD (W)
                (144723 OR 144 723)
L50         115 SEA FILE=WPIDS ABB=ON  PLU=ON  GABAPENTIN OR NEURONTIN OR GO
                3450 OR GOE 2450
L51       34231 SEA FILE=WPIDS ABB=ON  PLU=ON  GLYCEROL OR GLYCERIN?
L52        1664 SEA FILE=WPIDS ABB=ON  PLU=ON  XYLITO?
L53       15452 SEA FILE=WPIDS ABB=ON  PLU=ON  SORBIT? OR NEOSORB OR SORBEX
L54        4118 SEA FILE=WPIDS ABB=ON  PLU=ON  MANNIT?
L55           7 SEA FILE=WPIDS ABB=ON  PLU=ON  (L49 OR L50) AND (L51 OR L52 OR
                L53 OR L54)
L56           5 SEA FILE=WPIDS ABB=ON  PLU=ON  L55 NOT (ENCAPSUL? OR INTRANASAL
                ?)/TI


=> dup rem l57 l56 l41
FILE 'CAPLUS' ENTERED AT 17:19:59 ON 10 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 17:19:59 ON 10 SEP 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 17:19:59 ON 10 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V.  All rights reserved.
PROCESSING COMPLETED FOR L57
PROCESSING COMPLETED FOR L56
PROCESSING COMPLETED FOR L41
L58          10 DUP REM L57 L56 L41 (2 DUPLICATES REMOVED)
                ANSWERS '1-6' FROM FILE CAPLUS
                ANSWERS '7-9' FROM FILE WPIDS
                ANSWER '10' FROM FILE EMBASE

=> d ibib ab l58 1-10

L58  ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2002 ACS        DUPLICATE 1
ACCESSION NUMBER:         2002:256071  CAPLUS
DOCUMENT NUMBER:          136:284459
TITLE:                    Stable solid dosage forms of amino acids
INVENTOR(S):              Spireas, Spiridon
PATENT ASSIGNEE(S):       Sigmapharm, Inc., USA
SOURCE:                   PCT Int. Appl., 44 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
     WO 2002026263      A2   20020404       WO 2001-US30095   20010926
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
```

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002091159 A1 20020711 US 2001-928467 20010813

PRIORITY APPLN. INFO.: US 2000-235349P P 20000926
US 2001-928467 A 20010813

OTHER SOURCE(S): MARPAT 136:284459

AB Pharmaceutical formulations contain an amino acid which is susceptible to the formation of an undesirable lactam, and a stabilizer comprising a volatile alc., a nonvolatile alc., a water-immiscible **liq.** or solid, a **liq.** with a relatively low dielec. const., **liq**. and solid surfactants, an antioxidant, a ketone, an aldehyde, a solid polyethylene glycol of high mol. wt., polyvinylpyrrolidone, a derived cellulose, silicon dioxide, or a combination to inhibit the lactam formation. Thus, a formulation contained anhyd. **gabapentin** 400, corn starch 113, and water 100 mg/unit dose.

L58 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2

ACCESSION NUMBER: 2002:71907 CAPLUS
DOCUMENT NUMBER: 136:123679
TITLE: Enhancement of the action of central and peripheral nervous system agents with nitrous oxide
INVENTOR(S): Meyer, Petrus Johannes
PATENT ASSIGNEE(S): Pitmy International N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005851	A2	20020124	WO 2001-ZA99	20010719

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: ZA 2000-3643 A 20000719

AB The invention provided a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the CPNS agents selected from the group of compds. acting on the central or peripheral nervous system, and for a formulation of such agents characterized in that the agent is formulated with an administration medium which is characterized in that it comprises a **soln.** of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which administration medium includes at least one fatty acid or ester or other suitable deriv. thereof selected from the group consisting of oleic acid, linoleic acid, .alpha.-linolenic acid, .gamma.-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5.omega.3], decosahexaenoic acid [C22: 6.omega.3], ricinoleic acid and derivs. thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the **glycerol** -PEG esters and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils such as castor oil with ethylene oxide. **Solns.** of nitrous oxide were prepd.

L58 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:50461 CAPLUS
DOCUMENT NUMBER: 134:91168
TITLE: Method for making granules with masked taste and instant release of the active particle
INVENTOR(S): Nouri, Noureddine; Zuccarelli, Jean-Marc; Chauveau, Charles; Bruna, Etienne
PATENT ASSIGNEE(S): Laboratoires Prographarm, Fr.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001003672	A1	20010118	WO 2000-FR1855	20000630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2795962	A1	20010112	FR 1999-9047	19990708
BR 2000012250	A	20020326	BR 2000-12250	20000630
EP 1194125	A1	20020410	EP 2000-946045	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001006308	A	20011221	NO 2001-6308	20011221
US 2002098227	A1	20020725	US 2002-41389	20020108

PRIORITY APPLN. INFO.: FR 1999-9047 A 19990708
WO 2000-FR1855 W 20000630

AB The invention concerns a method for making coated granules with masked taste and instant release of the active principle which consists in: first, mixing the constituents of a powder comprising at least the active principle and a granular disintegrating agent; then, granulating the resulting powder, in the presence of a mixt. of carriers comprising at least a binding agent capable of binding the particles together to obtain grains; coating the grains formed by spraying a suspension comprising at least a coating agent and a membrane disintegrating agent; finally drying the resulting coated granules. Granules were prepd. according to above method contg. eletriptan salt 98.5, sodium croscarmellose 4.90, Et cellulose 20.40, polyoxyethylene glycol 4, sodium croscarmellose 3.70, silica 1.40, and aspartame 3.90 mg. The above granules were used to prep. a tablet with instant release.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:80040 CAPLUS
DOCUMENT NUMBER: 132:127733
TITLE: Stabilized solid preparations of 4-amino-3-substituted-butanoic acid derivatives and their manufacture
INVENTOR(S): Aomatsu, Akira
PATENT ASSIGNEE(S): Warner Lambert Co., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 34 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000034227	A2	20000202	JP 1999-133769	19990514

PRIORITY APPLN. INFO.: JP 1998-133112 A 19980515
OTHER SOURCE(S): MARPAT 132:127733
AB Solid prepns. of H2NCH2CR1R2CH2CO2H [I; R1 = H, OH, Me, Et; R2 = various (un)substituted hydrocarbyl (definitions are described in detail)], useful as nervous system agents for treatment of epilepsy, syncope, head trauma, cerebral dysfunction, Alzheimer disease, Huntington chorea, parkinsonism, etc., are manufd. by adding water-holding agents such as ethylene glycol, propylene glycol, **glycerin**, etc., and optionally excipients. The prepns. may addnl. contain neutral amino acids. Water-holding agents prevents deterioration of I due to lactam formation. **Gabapentin** was spray-coated with an **aq**. propylene glycol **soln**. to give powder contg. 0.003% lactam. The powder was stored in a sealed container at 60.degree. for 2 wk to show lactam content 0.011%, vs. 0.017% for control powder contg. no propylene glycol.

L58 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:753060 CAPLUS
DOCUMENT NUMBER: 131:356133
TITLE: Solid compositions containing .gamma.-aminobutyric acid derivatives
INVENTOR(S): Aomatsu, Akira
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9959572	A1	19991125	WO 1999-US10186	19990510
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2325045	AA	19991125	CA 1999-2325045	19990510
AU 9940733	A1	19991206	AU 1999-40733	19990510
BR 9910494	A	20010109	BR 1999-10494	19990510
EP 1077691	A1	20010228	EP 1999-924164	19990510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2000005765	A	20001114	NO 2000-5765	20001114

PRIORITY APPLN. INFO.: JP 1998-133122 A 19980515
JP 1998-133112 A 19980515
WO 1999-US10186 W 19990510
OTHER SOURCE(S): MARPAT 131:356133
AB The present invention provides a stabilized solid compn. contg. a 4-amino-3-substituted-butanoic acid deriv. which can be obtained by incorporating a humectant as a stabilizer. Bulk powders of **gabapentin** (250 g) were sprayed with 72 g water by means of a

fluidized granulator and then dried to give **gabapentin** granular powders A. A second batch of bulk powders of **gabapentin** (250 g) were sprayed with a **soln.** of 5 g propylene glycol in 67 g water by means of the fluidized granulator and then dried to give **gabapentin** granular powders B. The **gabapentin** granular powders A and B obtained were stored under conditions and then the lactam formed in each of the powders was detd. by HPLC. E.g., **gabapentin** bulk powders stored for 4 wk at 50.degree. and 85% humidity did not show any degrdn.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:768687 CAPLUS
DOCUMENT NUMBER: 130:162686
TITLE: MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening
AUTHOR(S): Irvine, Jennifer D.; Takahashi, Lori; Lockhart, Karen; Cheong, Jonathan; Tolan, John W.; Selick, H. E.; Grove, J. Russell
CORPORATE SOURCE: Affymax Research Institute (a Glaxo Wellcome Company), Santa Clara, 95051, USA
SOURCE: Journal of Pharmaceutical Sciences (1999), 88(1), 28-33
CODEN: JPMSAE; ISSN: 0022-3549
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The goal of this work was to investigate the use of MDCK (Madin-Darby canine kidney) cells as a possible tool for assessing the membrane permeability properties of early drug discovery compds. Apparent permeability (Papp) values of 55 compds. with known human absorption values were detd. using MDCK cell monolayers. For comparison, Papp values of the same compds. were also detd. using Caco-2 cells, a well-characterized in vitro model of intestinal drug absorption. Monolayers were grown on 0.4-.mu.m Transwell-COL membrane culture inserts. MDCK cells were seeded at high d. and cultured for 3 days, and Caco-2 cells were cultured under std. conditions for 21 to 25 days. Compds. were tested using 100 .mu.M donor **solns.** in transport medium (pH 7.4) contg. 1% DMSO. The Papp values in MDCK cells correlated well with those in Caco-2 cells (r2 = 0.79). Spearman's rank correlation coeff. for MDCK Papp and human absorption was 0.58 compared with 0.54 for Caco-2 Papp and human absorption. These results indicate that MDCK cells may be a useful tool for rapid membrane permeability screening.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L58 ANSWER 7 OF 10 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2002-171533 [22] WPIDS
DOC. NO. CPI: C2002-052992
TITLE: Composition useful for treatment of cerebral diseases e.g. epilepsy comprises pure and stable **gabapentin** having pH within a controlled range.
DERWENT CLASS: A96 B05
INVENTOR(S): PESACHOVICH, M; PILARSKI, G; SINGER, C
PATENT ASSIGNEE(S): (PESA-I) PESACHOVICH M; (PILA-I) PILARSKI G; (SING-I) SINGER C; (TEVA-N) TEVA PHARM IND LTD; (TEVA-N) TEVA PHARM USA INC
COUNTRY COUNT: 96
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001097782	A1	20011227	(200222)*	EN	25

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

US 2002045662 A1 20020418 (200228)
AU 2001066992 A 20020102 (200230)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001097782	A1	WO 2001-US19427	20010615
US 2002045662	A1 Provisional	US 2000-211966P	20000616
		US 2001-880922	20010615
AU 2001066992	A	AU 2001-66992	20010615

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001066992	A Based on	WO 200197782

PRIORITY APPLN. INFO: US 2000-211966P 20000616; US 2001-880922 20010615

AB WO 200197782 A UPAB: 20020409
NOVELTY - A composition comprises **gabapentin** initially containing less than 0.5 wt.% of its corresponding lactam and have pH 6.8 - 7.3.

ACTIVITY - Anticonvulsant; Tranquilizer; Vulnerary; Cerebroprotective.

MECHANISM OF ACTION - None given.

USE - For treatment of cerebral diseases such as epilepsy, faintness attacks, hypokinetics and cranial traumas.

ADVANTAGE - The problem of contamination of the toxic lactam compound during preparation and long-term storage of **gabapentin** disclosed in the prior arts is overcome. The composition is more stable as the conversion of **gabapentin** to its corresponding lactam does not exceed 0.2 wt.% ever after one year of storage at 25 deg. C and 60% humidity.

Dwg.0/0

L58 ANSWER 8 OF 10 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2002-171531 [22] WPIDS
DOC. NO. CPI: C2002-052990
TITLE: **Gabapentin** for treating cerebral diseases e.g. epilepsy contains lactam and an anion of a mineral acid.
DERWENT CLASS: A96 B03 B05
INVENTOR(S): PESACHOVICH, M; PILARSKY, G; SINGER, C; PILARSKI, G
PATENT ASSIGNEE(S): (TEVA-N) TEVA PHARM IND LTD; (PESA-I) PESACHOVICH M; (PILA-I) PILARSKY G; (SING-I) SINGER C; (TEVA-N) TEVA PHARM USA INC
COUNTRY COUNT: 96
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 2001097612 A1 20011227 (200222)* EN 26
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2001068426 A 20020102 (200230)
US 2002061931 A1 20020523 (200239)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001097612 A1		WO 2001-US19100	20010615
AU 2001068426 A		AU 2001-68426	20010615
US 2002061931 A1	Provisional	US 2000-211967P	20000616
		US 2001-880854	20010615

6,531,509

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001068426 A	Based on	WO 200197612

tablets

PRIORITY APPLN. INFO: US 2000-211967P 20000616; US 2001-880854 20010615

AB WO 200197612 A UPAB: 20020409
NOVELTY - **Gabapentin** (1-(aminomethyl)-1-cyclohexaneacetic acid) contains the corresponding lactam (less than 0.5%) and an anion of a mineral acid (20 - 100 parts per million (ppm)) and after one year of storage at 250C and 60% humidity gets converted to its corresponding lactam not exceeding 0.2 wt.%.
DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a pharmaceutical composition comprising **gabapentin** and further contains at least one adjuvant.
ACTIVITY - Cerebroprotective; Anticonvulsant; Tranquilizer; and Vulnerary.
MECHANISM OF ACTION - None given.
USE - For treating cerebral diseases e.g. epilepsy, faintness attacks, hypokinesis and cranial traumas and in treating geriatric patients.
ADVANTAGE - **Gabapentin** and its pharmaceutical formulations are stable even without meeting Augart's requirements of maintaining the anion of a mineral acid less than 20 ppm.
Dwg.0/0

L58 ANSWER 9 OF 10 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2001-050079 [06] WPIDS
DOC. NO. CPI: C2001-013807
TITLE: Controlled release and taste masking oral compositions comprising active ingredient incorporated in a matrix structure.
DERWENT CLASS: A11 A96 B07
INVENTOR(S): AJANI, M; FOSSATI, L; PEDRANI, M; VILLA, R
PATENT ASSIGNEE(S): (CIPN-N) CIP-NINETY TWO-92 SA; (COSM-N) COSMO SPA
COUNTRY COUNT: 94
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 2000076478 A1 20001221 (200106)* EN 25
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2000056801 A 20010102 (200121)
EP 1183014 A1 20020306 (200224) EN
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
NO 2001006108 A 20020124 (200225)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000076478	A1	WO 2000-EP5356	20000609
AU 2000056801	A	AU 2000-56801	20000609
EP 1183014	A1	EP 2000-942044	20000609
		WO 2000-EP5356	20000609
NO 2001006108	A	WO 2000-EP5356	20000609
		NO 2001-6108	20011214

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2000056801	A	Based on	WO 200076478
EP 1183014	A1	Based on	WO 200076478

PRIORITY APPLN. INFO: IT 2000-MI422 20000303; IT 1999-MI1317 19990614

AB WO 200076478 A UPAB: 20010126
NOVELTY - Controlled release and taste masking oral compositions comprise active ingredients incorporated in a matrix structure.
DETAILED DESCRIPTION - A controlled release and taste masking oral composition containing an active ingredient comprises:
(a) a matrix consisting of lipophilic compounds with melting point lower than 90 deg. C in which the active ingredient is at least partially dispersed;
(b) optionally an amphiphilic matrix;
(c) an outer hydrophilic matrix in which (a) and (b) are dispersed; and
(d) optionally other excipients.
ACTIVITY - Analgesic; antitussive; bronchodilator, antipsychotic; antiparkinson; antihistamine; antiinflammatory; antidiarrheal; spasmolytic; anxiolytic; antidiabetic; cathartic; antiepileptic; antimicrobial.
MECHANISM OF ACTION - Selective beta -2 antagonist; calcium antagonist; antihistamine,
USE - For oral administration of active ingredients.
Dwg.0/0

L58 ANSWER 10 OF 10 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 96067248 EMBASE
DOCUMENT NUMBER: 1996067248
TITLE: In vitro assessment of **oral** delivery for hexapeptide endothelin antagonists.
AUTHOR: Stewart B.H.; Reyner E.L.; Tse E.; Hayes R.N.; Werness S.; He J.X.; Cody W.L.; Doherty A.M.

CORPORATE SOURCE: Pharmacokinetics/Drug Metabol. Dept., Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company,Ann Arbor, MI 48105, United States
SOURCE: Life Sciences, (1996) 58/12 (971-982).
ISSN: 0024-3205 CODEN: LIFSAK
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Endothelin (ET-1) is a 21-amino acid, vasoconstrictive peptide originally isolated from endothelial cells. It is one member of a class of potent, purportedly paracrine substances that act at receptors in multiple target organs. Antagonists to the receptor subtypes, ET(A) and ET(B), have been designed around the hydrophobic carboxy-terminus of ET-1. The resulting hexapeptides possess low nanomolar receptor affinity, but face formidable challenges to oral delivery, given their peptidic nature. Hence, it was important to discriminate between analogs, as well as to optimize structural features combining binding potency with stability in intestinal fluids and permeability across biological membranes. PD 142893 (Ac-DDip16-Leu-Asp-Ile-Ile-Trp21) and PD 145065 (Ac-DBhg16-Leu-Asp-Ile-Ile-Trp21), as well as the N-methyl-isoleucine20 analogs were studied, where DDip = 3,3-diphenylalanine and DBhg = 10,11-dihydro-5H-dibenzo[a,d]cycloheptene glycine. Analyses were conducted with specific HPLC methods. Permeabilities across CACO-2 cell monolayers ranged from 2.0 x 10-4 to 6.3 x 10-4 cm/min. The results suggested that these compounds can be absorbed in vivo, based on comparison of permeabilities with those obtained with reference compounds. Much greater differences were observed between the analogs when stability half-lives were compared after incubation in rat intestinal perfusate. The parent peptides, PD 142893 and PD 145065, were unstable, with half-lives less than 20 min. N-Methylation of Ile20 resulted in large increases in stability half-lives to greater than 500 min. Enzyme inhibition studies demonstrated the involvement of carboxypeptidase A in production of the primary metabolite, the des-Trp derivative. Identification of the primary metabolite of the parent peptide was made by differential UV scanning at 214/280 nm and mass spectral analyses.

=> file home
FILE 'HOME' ENTERED AT 17:21:03 ON 10 SEP 2002